JHVEPhoto Vanda Pharmaceuticals ( NASDAQ: VNDA ) has sent a letter to FDA Commissioner Robert Califf asserting that the review of the New Drug Application for its drug tradipitant was flawed and that the agency has not adequately responded to its complaints about.
Back to Health Page
